How Advanced are Nanocarriers for Effective Subretinal Injection?
Jia-Xin Guan,Yan-Ling Wang,Jia-Lin Wang
DOI: https://doi.org/10.2147/ijn.s479327
IF: 7.033
2024-09-10
International Journal of Nanomedicine
Abstract:Jia-Xin Guan, 1, 2 Yan-Ling Wang, 1, 2, &ast Jia-Lin Wang 1, 2, &ast 1 Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Institute of Ophthalmology, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Lin Wang; Yan-Ling Wang, Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China, Email ; Subretinal injection (SR injection) is a commonly used method of ocular drug delivery and has been mainly applied for the treatment of neovascular age-associated macular degeneration (nAMD) and sub-macular hemorrhage (SMH) caused by nAMD, as well as various types of hereditary retinopathies (IRD) such as Stargardt's disease (STGD), retinitis pigmentosa (RP), and a series of fundus diseases such as Leber's congenital dark haze (LCA), choroidal defects, etc. The commonly used carriers of SR injection are mainly divided into viral and non-viral vectors. Leber's congenital amaurosis (LCA), choroidal agenesis, and a series of other fundus diseases are also commonly treated using SR injection. The commonly used vectors for SR injection are divided into two categories: viral vectors and non-viral vectors. Viral vectors are a traditional class of SR injection drug carriers that have been extensively studied in clinical treatment, but they still have many limitations that cannot be ignored, such as poor reproduction efficiency, small loading genes, and triggering of immune reactions. With the rapid development of nanotechnology in the treatment of ocular diseases, nanovectors have become a research hotspot in the field of non-viral vectors. Nanocarriers have numerous attractive properties such as low immunogenicity, robust loading capacity, stable structure, and easy modification. These valuable features imply greater safety, improved therapeutic efficacy, longer duration, and more flexible indications. In recent years, there has been a growing interest in nanocarriers, which has led to significant advancements in the treatment of ocular diseases. Nanocarriers have not only successfully addressed clinical problems that viral vectors have failed to overcome but have also introduced new therapeutic possibilities for certain classical disease types. Nanocarriers offer undeniable advantages over viral vectors. This review discusses the advantages of subretinal (SR) injection, the current status of research, and the research hotspots of gene therapy with viral vectors. It focuses on the latest progress of nanocarriers in SR injection and enumerates the limitations and future perspectives of nanocarriers in the treatment of fundus lesions. Furthermore, this review also covers the research progress of nanocarriers in the field of subretinal injection and highlights the value of nanocarrier-mediated SR injection in the treatment of fundus disorders. Overall, it provides a theoretical basis for the application of nanocarriers in SR injection. Keywords: nanoparticles, subretinal injection, drug delivery, non-viral vectors, nanomedicine, gene therapy SR injection is a commonly used method for intraocular drug delivery. It is widely utilized in the treatment of nAMD 1 and SMH due to nAMD, 2 as well as different types of IRDs (eg RPE65-associated LCA, 3 CHM-associated choroidal agenesis, 4 MERTK-associated RP, 5 and ABCA4-associated STGD 6 ). SR injection has become the preferred therapy for treating IRD, and various vectors have been developed and tailored for different types of IRD. 7 In the case of SMH, the preferred method is subretinal injections of tissue plasminogen activator (tPA), which is considered the gold standard. 8 Moreover, for treating nAMD, which involves neovascularization, a promising approach involves combining different drugs that inhibit neovascularization with carriers and injecting them into the subretinal space (SRS). This method has shown a positive impact on disease control. 9 A series of therapeutic methods, such as laser therapy, vitrectomy surgery, and gene therapy through intravitreal drug delivery routes, have been developed over the years. However, these methods still have shortcomings, including poor therapeutic effect and short duration. These shortcomings can be perfectly remedied by SR injection. SR injection can deliver drugs directly to the SRS, which is the potential space between photoreceptors and retinal pigment epithelial (RPE) cells in the outer layer of the retina. This avoids the need for long-distance delivery through the vitreous body and the barrier e -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology